Spots Global Cancer Trial Database for A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Official Title: Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
Study ID: NCT06311578
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Johnson & Johnson Enterprise Innovation Inc Clinical Trial
Affiliation: Johnson & Johnson Enterprise Innovation Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
